drugset / Trial / NCT03818893
Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII
Phase 2
Unknown
46 enrolled
Osaka University
ISHIHARA SANGYO KAISHA,LTD. Japan · collabMerck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center, open-labeled, non-randomized, single arm investigator-initiated trial to evaluate the safety and efficacy of GEN0101 and Pembrolizmub combination in patients with advanced melanoma.
Timeline
- Start
- 2019-03
- Primary completion
- 2021-12-31
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GEN0101 | Unknown | 60000 unknown | Other |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |